TY  - JOUR
AU  - Conteduca, V
AU  - Wetterskog, D
AU  - Sharabiani, M T A
AU  - Grande, E
AU  - Fernandez-Perez, M P
AU  - Jayaram, A
AU  - Salvi, S
AU  - Castellano, D
AU  - Romanel, A
AU  - Lolli, C
AU  - Casadio, V
AU  - Gurioli, G
AU  - Amadori, D
AU  - Font, A
AU  - Vazquez-Estevez, S
AU  - Gonzalez Del Alba, A
AU  - Mellado, B
AU  - Fernandez-Calvo, O
AU  - Méndez-Vidal, M J
AU  - Climent, M A
AU  - Duran, I
AU  - Gallardo, E
AU  - Rodriguez, A
AU  - Santander, C
AU  - Saez, M I
AU  - Puente, J
AU  - Gasi Tandefelt, D
AU  - Wingate, A
AU  - Dearnaley, D
AU  - Demichelis, F
AU  - De Giorgi, U
AU  - Gonzalez-Billalabeitia, E
AU  - Attard, G
PY  - 2017
DO  - 10.1093/annonc/mdx155
UR  - http://hdl.handle.net/10668/11171
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital...
LA  - en
PB  - Elsevier
KW  - Abiraterone
KW  - Androgen receptor
KW  - Biomarker
KW  - Castration-resistant prostate cancer
KW  - Enzalutamide
KW  - Plasma DNA
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Androstenes
KW  - Antineoplastic Agents, Hormonal
KW  - Benzamides
KW  - Biomarkers, Tumor
KW  - Circulating Tumor DNA
KW  - DNA Mutational Analysis
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Europe
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Multiplex Polymerase Chain Reaction
KW  - Multivariate Analysis
KW  - Mutation
KW  - Nitriles
KW  - Odds Ratio
KW  - Patient Selection
KW  - Phenylthiohydantoin
KW  - Precision Medicine
KW  - Predictive Value of Tests
KW  - Proportional Hazards Models
KW  - Prospective Studies
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Receptors, Androgen
KW  - Risk Factors
KW  - Time Factors
KW  - Treatment Outcome
TI  - Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
TY  - research article
VL  - 28
ER  -